CIP
ADMA icon

Convergence Investment Partners’s ADMA Biologics ADMA Stock Holding History

Convergence Investment Partners’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-57,052
Closed -$1.14M – 252
2024
Q3 		$1.14M Buy
+57,052
New +$887K 0.31% 107

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Convergence Investment Partners's ADMA Position: Q4 2024 in Review

Convergence Investment Partners sold out of ADMA Biologics (ADMA) in Q4 2024, closing a stake of 57,052 shares — an estimated $1.14M sold.

Convergence Investment Partners first reported a position in ADMA in Q3 2024 and held it in 1 quarter. The position peaked at $1.14M in Q3 2024. 322 funds tracked by Wall St. Rank hold ADMA as of Q4 2024.

  • Convergence Investment Partners reported no remaining ADMA Biologics position as of Q4 2024 after selling out during the quarter.
  • Convergence Investment Partners sold 57,052 ADMA Biologics shares in Q4 2024, an estimated $1.14M.
  • Convergence Investment Partners first reported a position in ADMA Biologics in Q3 2024 and held it in 1 quarter.
  • Convergence Investment Partners's ADMA Biologics position peaked at $1.14M in Q3 2024.
  • 322 funds tracked by Wall St. Rank held ADMA Biologics as of Q4 2024.

Based on Convergence Investment Partners's 13F filing for Q4 2024, filed 31 Jan 2025.